Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24065518 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Quentin Dominique Thomas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Montpellier Cancer Institute (ICM), 34090 Montpellier, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A combination of tyrosine kinase inhibitors (TKIs) is likely to be a therapeutic option for numerous oncological situations due to high frequency of oncogenic addiction and progress in precision oncology. Non-small cell lung cancer (NSCLC) represents a subtype of tumors for which oncogenic drivers are frequently involved. To the best of our knowledge, we report the first case of a patient treated with three different TKIs. Osimertinib and crizotinib were administered concurrently for an epidermal growth factor receptor (EGFR)-mutated NSCLC developing a MET amplification as a resistance mechanism to osimertinib. Simultaneously, imatinib was administered for a metastatic gastrointestinal stromal tumor. The progression-free survival was 7 months for both tumors with this tritherapy. The use of therapeutic drug monitoring to assess plasma concentrations of each TKI was a powerful tool to manage the toxicity profile of this combination (creatine phosphokinase elevation) while preserving an optimal exposure to each TKI and treatment efficacy. We observed an imatinib over-exposition related to crizotinib introduction, probably explained by drug–drug interaction mediated by crizotinib enzymatic inhibition on cytochrome P-450 3A4. Posology adjustment due to therapeutic drug monitoring was probably involved in the good survival outcome of the patient. This tool should be used more routinely for patients treated by TKIs to prevent co-treatment interactions and, in particular, for patients receiving TKI combinations to obtain optimal therapeutic exposure and efficacy while reducing possible side-effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Montpellier Cancer Institute (ICM), 34090 Montpellier, France.
- Montpellier Cancer Research Institute (IRCM), University of Montpellier (UM), 34090 Montpellier, France.
- Pharmacokinetics Laboratory, Faculty of Pharmacy, University of Montpellier, 34090 Montpellier, France.
ORCID-Profile: Quentin Dominique Thomas, Xavier Quantin, Fanny Leenhardt
Zitieren
APA
Thomas, Q. D., Firmin, N., Mbatchi, L., Evrard, A., Quantin, X., & Leenhardt, F. (2023). Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065518
Vancouver
Thomas QD, Firmin N, Mbatchi L, Evrard A, Quantin X, Leenhardt F. Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065518
BibTeX
@article{Thomas2023,
author = {Thomas, Quentin Dominique and Firmin, Nelly and Mbatchi, Litaty and Evrard, Alexandre and Quantin, Xavier and Leenhardt, Fanny},
title = {Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24065518}
}
EUVIMED